Filing Flows › Zevra Therapeutics (ZVRA) › Q3 2026 › vs Q2 2026
Zevra Therapeutics (ZVRA) Q3 2026 vs Q2 2026 (quarter over quarter)
Zevra Therapeutics's revenue fell $1.9M (-5%) from $39.7M in Q2 2026 to $37.8M in Q3 2026. Operating margin 30.7% against 42.3% (-11.6 pts).
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 30.7% | 42.3% | -11.6 pts |
| Net margin | 50.9% | 22.1% | +28.8 pts |
| Free cash flow margin | 26.0% | 42.4% | -16.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $37.8M | $39.7M | −$1.9M | -5% |
| Other income, net | $8.1M | −$4.0M | $12.1M | — |
| Operating profit | $11.6M | $16.8M | −$5.2M | -31% |
| Costs & expenses | $26.2M | $22.9M | $3.3M | +14% |
| Pre-tax earnings | $19.7M | $12.8M | $6.9M | +54% |
| Cost of revenue | $1.8M | $1.5M | $269K | +18% |
| Research & development | $4.9M | $4.5M | $451K | +10% |
| SG&A | $19.1M | $16.6M | $2.6M | +16% |
| Other operating costs | $315K | $316K | −$1K | -0.3% |
| Net earnings | $19.2M | $8.8M | $10.5M | +119% |
| Income tax | $510K | $4.0M | −$3.5M | -87% |
| Depreciation & amortization | $378K | $364K | $14K | +4% |
| Share-based compensation | $2.7M | $3.0M | −$297K | -10% |
| Working capital & other | $12.2M | −$4.9M | $17.2M | — |
| Operating cash flow | $10.0M | $17.0M | −$7.0M | -41% |
| Free cash flow (OCF − capex) | $9.8M | $16.8M | −$7.0M | -42% |
| Capital expenditures | $238K | $217K | $21K | +10% |
Questions
How much did Zevra Therapeutics's revenue grow quarter over quarter in Q3 2026?
Zevra Therapeutics's revenue fell $1.9M (-5%) from $39.7M in Q2 2026 to $37.8M in Q3 2026. Operating margin 30.7% against 42.3% (-11.6 pts).